Qualigen Therapeutics, Inc. (“Qualigen” or “the Company,” Nasdaq: QLGN) will be presenting five posters at the American Association for Cancer Research (AACR) Annual Meeting 2023 to be held April 14-19 in Orlando, FL. The AACR Conference is a focal point of the cancer research community, where scientists, clinicians, other healthcare professionals, survivors, patients, and advocates gather to share the latest advances in cancer science and medicine. The Company will be presenting four posters regarding its lead program, QN-302, and one poster regarding an in-vivo study of program QN-247 in Triple Negative Breast Cancer (TNBC).

About QN-302: QN-302 is a small molecule G-Quadruplex (G4)-selective transcription inhibitor in development for the treatment of G4-expressing tumors, such as pancreatic cancer (PDAC), prostate cancer, sarcomas, Gastrointestinal Stromal Tumors (GIST), and others. Orphan Drug Designation (ODD) was granted by the FDA in January of this year for pancreatic cancer. QN-302 is currently in IND enabling studies toward submission of an Investigational New Drug (IND) application (in the coming months).

About QN-247: QN-247 is a nucleolin-targeted therapeutic with potential indications against nucleolin expressing malignancies such as Triple Negative Breast Cancer (TNBC), Acute Myeloid Leukemia (AML), Glioblastoma (GBM), and others. The company is currently seeking partners to advance QN-247 program in TNBC and other malignancies.